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Objective:  Data  on duration  and  long-term  protective  effects  of  hepatitis  A vaccines  (HepA)  have  not  been
reviewed  using  a systematic  approach.  Our  objective  is  to  provide  a comprehensive  review  of  evidence
on  the  duration  of  protection  achieved  by  HepA,  which  is needed  for revising  existing  vaccine  policies.
Limitations  in  data  availability  and  implications  for  future  research  in  this  area  are  discussed.
Methods: A  systematic  literature  review  was  conducted  including  all studies  published  between  1997
and  2011  reporting  on  long-term  protection  of HepA.  The  outcomes  considered  were  hepatitis  A virus
(HAV)  infection  and  sero-protection  measured  by  anti-HAV  antibodies  after  follow-up  times  of  over  5
years  post-vaccination.
Results:  299  studies  were  identiﬁed  from  MEDLINE  and  51 studies  from  EMBASE.  13  manuscripts  met  our
inclusion  criteria.  The  maximum  observation  times  and  reported  persistence  levels  of  sero-protective
anti-HAV  antibodies  was  15  years  for  live  attenuated  HepA  and  14  years  for  inactivated  HepA.  All data
were  from  observational  studies  and  showed  that  higher  number  of doses  of  live attenuated  vaccine  led
to  higher  seropositivity  and  GMT,  but dosage  and  schedule  did  not  signiﬁcantly  impact  the  long-term
protection  following  inactivated  vaccine.  Few  comparisons  were  made  between  the  two vaccine  types
indicating  highest  levels  of  antibody  titers  achieved  by  multiple  doses  of  live  attenuated  vaccines  7 years
post-vaccination.
Conclusion:  Available  data  indicate  that  both  inactivated  and  live  attenuated  HepA  are  capable  of providing
protection  up  to 15  years  as  deﬁned  by currently  accepted,  conservative  correlates  of protection.  Further
investigations  are  needed  to  continue  to  monitor  the  long-term  protection  afforded  by these  vaccines.
Standardized  methods  are  required  for vaccine-follow-up  studies  including  assessment  of  co-variables
potentially  affecting  long-term  protection.
.© 2012 Jördis  Jennifer  Ott.  Published  by  Elsevier  Ltd.  
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cines/formulations safety and efﬁcacy issues of HAV vaccine
(d)  the assessment of other factors inﬂuencing antibody devel-
opment, including single and multiple dose, variability in
schedule, time and type of vaccine administrationJ.J.  Ott et al. / Va
. Introduction
Recent estimates indicate a global incidence of hepatitis A of
.9% with 119 million individuals having been infected with the
irus in 2005 [1]. Although hepatitis A is a self-limiting disease of
he liver and the virus itself is not cytopathic, its clinical manifesta-
ions can be severe leading to an estimated 34,000 deaths in 2005
1]. Severity of the disease is strongly age-dependent. Among chil-
ren below ﬁve years of age at the time of infection, 80–95% of
AV infections remain asymptomatic whereas in adults, 70–95% of
nfections result in clinical illness [2,3].
Infection with HAV can induce lifelong immunity, which is indi-
ated by seroprevalence of antibodies against HAV (anti-HAV). In
ub-Saharan Africa and other low income regions, almost 100% of
lder children and adults have acquired immunity. High income
egions including Western Europe and North America have gener-
lly low anti-HAV endemicity but there were increases observed
etween 1990 and 2005 [4]. Improvements in water supply and
anitation standards in many parts of the world have led to better
hild survival and many of these children reach adulthood without
aving been exposed to hepatitis A virus. Paradoxically, this factor
s responsible for increasing HAV-morbidity and -mortality in adult
ife, when the disease is generally more severe.
Vaccines against the hepatitis A virus have been commercially
vailable since the 1990s and there are two types, inactivated and
ive attenuated hepatitis A vaccines. The ﬁrst inactivated Hepatitis
 vaccines were produced from a HAV propagated in cell culture,
ubsequently puriﬁed and inactivated by exposure to formalin. Cur-
ently, four inactivated monovalent HAV vaccines are commercially
vailable (Havrix®, Vaqta®, Avaxim®, and Epaxal®) and include
ntigen prepared from different strains of the HAV. Inactivated hep-
titis A vaccines have proven to be among the most immunogenic,
afe and well-tolerated vaccines [5–7].
In order to produce the live attenuated vaccine, the disease pro-
ucing ‘wild type’ virus is ﬁrst modiﬁed in the laboratory. This
attenuated’ virus still retains the ability to replicate and stimu-
ate a host immune response but should not cause clinical disease
n vaccination. Although live attenuated hepatitis A vaccines are
omparably efﬁcacious and immunogenic, there is so far insufﬁ-
ient evidence obtained from trials to comment on their safety
ffectiveness [5].
WHO  vaccine recommendations have not been updated since
000. They include a call for both vaccination of individuals with
n increased risk of contracting HAV infection in low endemic areas
nd large-scale childhood vaccination in intermediate endemicity
ountries. Large-scale vaccination is not recommended for highly
ndemic countries given the high prevalence of anti-HAV indicating
revious infection [2]. There are no worldwide recommendations
or use of hepatitis A vaccine booster doses after having completed a
ull vaccination course. This might be related to the lack of observed
nd reported data on the persistence of anti-HAV antibodies and the
uantiﬁed duration of protection of hepatitis A vaccines. Several
athematical models have been applied addressing the long-term
ersistence of detectable antibodies [8–12] and it was  estimated
hat anti-HAV antibodies persist on average for more than 20–25
ears [9]. Recently published modeling data indicated a median
redicted duration of protection over 50 years using cut-off levels
f ≥10 mIU/ml and of 45 years using cut-off levels of ≥20 mIU/ml
13].
In 2003, an expert group published a consensus statement on
ong-term protection of hepatitis A vaccines, which involved a
on-systematic information search [14]. Based on existing data
nd models (e.g. Iwarson et al. [15] and Landry et al. [16]), the
uthors concluded that there is no data to support the need for
 booster dose in immunocompetent individuals who  received a
ull vaccination course. This conclusion was based on the ﬁnding1 (2012) 3– 11
that  long-term protection against hepatitis A infection does not
depend on HAV-antibodies but is conferred by immune memory
in a way  that an anamnestic response can prevent disease in indi-
viduals previously vaccinated with inactivated hepatitis A vaccine
[10,17].
Although the duration of protection of anti-HAV antibodies may
have important implications for human susceptibility and for cost-
effectiveness of vaccination, no systematic review on the duration
and long-term protective effects of hepatitis A vaccines has been
published. In light of this gap, our objective is to provide a com-
prehensive and reliable review of existing data on the duration of
protection afforded by hepatitis A vaccines, which could help revis-
ing existing hepatitis A vaccine recommendations. We evaluated
studies from 1997 to 2011 on this topic and discuss limitations in
data availability and implications for future research in this area.
2. Methods
The key objective of this review was  to assess the long-term efﬁ-
cacy of monovalent hepatitis A vaccines. We  developed a search
strategy that aimed to identify those articles or abstracts that con-
tain a term related to both hepatitis A vaccine (1) and long-term
protection (2). We  added a third concept to exclude studies that
evaluated combined hepatitis A and B vaccines.
We searched several major electronic databases including:
Cochrane Library, MEDLINE and EMBASE. The Cochrane Library and
MEDLINE search included the years from 1997 to 2011 and was  sup-
plemented by an EMBASE search which included the most recent
years of publication, 2010 and 2011 (adapted search strategies
available from Annex 1 and 2). We  included all types of available
studies, irrespective of age, sex, and ethnic origin, route of vac-
cine administration, dosage, schedule, and irrespective of type of
intervention (inactivated hepatitis A vaccine and live attenuated
hepatitis A vaccine). The search was not restricted to any language.
Since hepatitis A vaccines became available in the early 1990s and
the goal was to identify long-term protective effects, the MEDLINE
search was  restricted to articles published after 1996 and citations
were included up to 25 July 2011. The primary outcome consid-
ered was  HAV infection. Secondary outcomes included immune
response as measured by the persistence of anti-HAV antibody (%
of seropositivity), and differences in immune response measured
by Geometric mean titers (GMT) of anti-HAV antibodies in mIU/ml.
The following studies and study types were excluded:
(1) Studies providing results that were obtained exclusively from
mathematical modeling of long-term protection or vaccine
impact.
(2) Studies that assessed hepatitis A vaccine safety and immuno-
genicity not related to long-term protection, or those assessing
protective effects ≤60 months after vaccination.1
(3) The study objective was  not related to long-term impact assess-
ment  of HAV vaccine but was
(a) the assessment and comparison of diagnostic tests, detec-
tion methods, and laboratory proﬁles
(b)  the assessment of economic and cost-effectiveness issues
around HAV vaccines
(c) the assessment of co-administration with other vac-1 Depending on the study, time after hepatitis A vaccination is provided in months
after  ﬁrst dose or last dose vaccination with intervals between ﬁrst and last dose of
<12 months.
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Total  number  of citations  fou nd usi ng 
search conc epts  1 (hepatitis A vaccine), 2 
(long-term  pro tection),  3 (eti ology):  562  
Number  of  citations on mo novalent 
hepatitis  A vaccine,  publi shed  1997  and  
aft er,  and  to be screen ed:  299  
Combined hep atitis A and  B va cci ne: 99 
Pub lish ed be fore 19 97: 16 4
1) Ma thema tical  mo delling : 2 
2) ≤60  months aft er vaccina tion: 45  in cl. 3 reviews 
3) Not related to  lo ng-term pr otection 
 3a)  diag nostic s and  lab:  9 
  3b) ec onomic costs: 6 incl. 1 review 
 3c)  co-ad min.:  6 
 3d ) othe r impacting  fact ors: 25  
 3e)  post expo sure  ad min:  9 
  3f)  diff eren t hep A vaccine s compa red : 6 
  3g) no  direct relation to  research 
 quest ion : 20 
4) Serop reva lence  stud ies : 90 
5) Hi gh risk  gr oups  and no t long- term  pro tec tion : 41 
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pFig. 1. Trial ﬂow ME
(e) outbreak investigations and postexposure administration
(f) the comparison of different hepatitis A vaccines in terms of
immunogenicity/interchangeability/tolerability
(g) other studies not or indirectly related to hepatitis A vaccine
4) Study types were seroprevalence studies, studies on country-
speciﬁc  epidemiology, (sub-) population surveys on incidence
and  prevalence of HAV infection and prevalence of anti-HAV
antibody.
5) The study focused on immune response, immunogenicity,
safety or efﬁcacy of HAV vaccine (not long-term protection)
among particular high risk groups, mainly patients with liver
disease  or HIV-AIDS.
6) Opinions, letters, comments, reports, and expert reviews on
HAV  vaccine recommendations, outcomes, coverage and oth-
ers.
We selected potentially eligible articles using a two  stage
rocess. First, title and abstracts from all citations identiﬁed
y MEDLINE and EMBASE databases were screened. The second
creening involved retrieving the full text of those citations not
xcluded in the ﬁrst step while applying the speciﬁc criteria related
o study type and objective. Translations were obtained for non-
nglish citations, which were considered to be relevant, based
n title and abstract screening. We  then extracted the following
ata: number of participants, study location, intervention and com-
arison characteristics (vaccine type, vaccine schedule, number of
Total  number  of citations  fou nd usi ng 
adapted  sear ch conc epts 1- 4, 2010- 2011:
51 
Dup
Dup
1)/2
3) N
  
  
4) S 
5) H 
(be
6) C 
Number  of  citations  select ed app lying  all  
exclus ion  crite ria  and after  ful l text  
screening : 1
Fig. 2. Supplementary EMBASE eleE electronic search.
doses, length of follow up) and the outcome of interest (HAV infec-
tion, anti-HAV antibody persistence, GMT/GMC).
3. Results
From 1997 to 2011, 299 potentially relevant citations (Annex
3, Fig. 1) were identiﬁed from MEDLINE out of which 53 were
published in other languages than English, mainly in Chinese (21
articles. Other languages used were Russian (8), Spanish (6), French
(5), German (4), Polish (2), and Korean (2). Each of the following
languages provided one citation: Portuguese, Romanian, Hebrew,
Czech, and Croatian. After title and abstract screening, full text was
obtained for 33 English citations and 5 Chinese citations.
The  EMBASE search resulted in 51 citations from 2010 and 2011
(Annex 4). Out of these, 10 citations were duplicates in EMBASE
and 12 were identiﬁed by the two data bases for the respective
years. There were 27 citations excluded based on the criteria speci-
ﬁed in the method section. 11 of them were seroprevalence studies
(Fig. 2). After title and abstract screening, full text was  obtained for
two citations uniquely identiﬁed by EMBASE, one of which met  the
inclusion criteria (Fig. 2).
Overall, the majority of studies (101 citations) obtained using
the search strategy were observational seroprevalence studies of
anti-HAV or immunogenicity studies assessing the efﬁcacy of hep-
atitis A vaccines up to a few months after initial and/or booster
vaccination. A number of investigations were available evaluat-
ing the protective effects of hepatitis A vaccines up to 48 month/4
licates in  EMBASE: 10 
licates both da tabases:  12 
): - 
ot related to  lo ng-term pr otection 
3g) no  direct relation to  research 
question : 13 
eropreva lence  stud ies : 11 
igh risk  gr oups  and not  long-term  protec tion  
low 5 years  of pro tec tion  assessed) : 3 
overage  issues/o pinions:  1 
ctronic search, 2010–2011.
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ears (e.g. [18]) and 60 months/5 years after vaccine administration
19–22].
Out of the 13 studies that met  our inclusion criteria, 8 reported
n inactivated hepatitis A vaccines and 5 reported on live attenu-
ted vaccine. Two of these studies compared the two  vaccine types.
otential study limitations including loss to follow-up and sam-
le size are addressed in the discussion section and additionally
ighlighted in Tables 1 and 2.
.1. Inactivated hepatitis A vaccine
Studies using the inactivated hepatitis A vaccines HAVRIX,
PAXAL, and VAQTA were mainly conducted in high income and
ow anti-HAV prevalence countries (apart from Argentina [23] and
hina [27]) and were observational follow-up studies of cohorts
rom randomized vaccine trials. All studies reported secondary
utcomes such as seropositivity rates and GMC/GMT of anti-HAV
ntibodies. The two studies with the longest follow-up times were
one in children, one in Argentina [23] and the other one in the
S [24]. Byrd et al. [24] found protective GMC  to persist for 14
ears after the last vaccine dose, independent of schedule. The
tudy among Argentinean children also reported protective GMC  of
90.91 mIU/ml (95% CI: 282.2–499.5; range: 36–1860 mIU/ml) up
o year 10 after the second/booster dose [23]. A study conducted
n Switzerland among adults which reported a similar long dura-
ion of protection revealed protective levels of HAV IgG antibodies
GMC 526 mIU/ml; 95% CI: 439–630 mIU/ml) up to 11 years after
he second vaccine dose [13].
Studies meeting the inclusion criteria but reporting shorter
ntervals of protection (between 5.5 years and 6 years after last
accine dose) did not only compare GMC  over time but included
omparisons with a different inactivated hepatitis A vaccines, [25]
ifferent vaccine schedules [9], and different dosages (180, 360,
20 El.U) [11]. It appeared that none of these variables impacted
igniﬁcantly on the long-term protective levels of inactivated hep-
titis A vaccine. Van Herck and Van Damme  [9] concluded that GMT
evels 5.5 years post-booster dose were not affected by the sched-
le (0–6 or 0–12 month) in which HAVRIX was administered. The
nly available study comparing different dosage of inactivated hep-
titis A vaccine regarding long-term protective GMT  [11] did not
nd statistically signiﬁcant differences in GMT  up to year 6 post-
ooster vaccination between three different dosage groups (180,
60, 720 El.U). However, higher dosage resulted in higher observed
MT. The study that compared two inactivated hepatitis A vaccines
nd their interchangeability reported that long-term protection as
easured by GMT  was similar in all four vaccine groups studied
25].
An investigation compared long-term protection of hepatitis
 vaccine between HIV infected individuals and historically HIV-
ninfected adults and reported similarly long follow-up times as
he studies done in healthy adults. In this study, Crum-Cianﬂone
t al. [26] found protective levels of HAV IgG antibodies of GMC
4 mIU/ml in HIV-infected individuals up to 6–10 years post sec-
nd dose vaccination with VAQTA or HAVRIX. There was no
igniﬁcant difference in sero-response in a comparison between
IV-uninfected and HIV-infected persons, however, a lower pro-
ortion of sero-responders and lower GMC  responses was observed
mong HIV-infected persons [26].
Inactivated hepatitis A vaccine was also the primary interven-
ion in one study that compared the two hepatitis A vaccine types
inactivated and live attenuated) regarding their long term protec-
ion in children [27]. The observation time in the group vaccinated
ith live attenuated hepatitis A vaccine was only 3.6 years, whereas
ecipients of inactivated hepatitis A vaccine were followed-up
or ten years. No signiﬁcant differences in long-term protective
nti-HAV titers were seen between the two vaccine types, but1 (2012) 3– 11
conclusions  drawn from this direct comparison are limited due to
different follow-up periods.
3.2.  Live attenuated hepatitis A vaccines
All studies assessing duration of protection from live attenuated
hepatitis A vaccines were conducted among children in China and
were observational follow-up studies of cohorts from randomized
vaccine trials. Two  publications by Zhuang et al. [28,29] reported
on the primary outcome measure incident hepatitis A cases in
addition to presenting secondary outcomes including seropositi-
vity rates and GMC/GMT [28,29]. One of these publications reports
the longest follow-up time and found protective GMT  levels of
128 mIU/ml up to 15 years post-vaccination [29]. No hepatitis case
had occurred after the 15 years [29]. Results that were published
earlier from the same study [28] showed a GMT  of 145 mIU/ml at
year 10 after vaccination with live attenuated hepatitis A vaccine.
Two  other studies compared the long-term protective effects of
live attenuated hepatitis A vaccines by number of doses admin-
istered [30,31]. Both investigations found signiﬁcant differences
between the single and multiple dose groups with higher GMC  in
groups receiving multiple doses of live attenuated hepatitis A vac-
cine 8 years post-vaccination. Sero-conversion rates also differed
between the two dose groups in the two studies: Those children
having received more than one dose of the vaccine had higher sero-
positivity at year 8 (100% versus 71–75% [30]; 98% versus 71.6% [31]
indicating higher levels of sero-protection achieved by increasing
number of live attenuated vaccine doses.
One study included a multi-dimensional comparison of live
attenuated hepatitis A vaccine. The vaccine was compared accord-
ing to different schedules and also with inactivated hepatitis A
vaccine. Overall, Liu et al. [32] found signiﬁcant differences in
antibody GMC  between both vaccine types and between differ-
ent schedules: children vaccinated using a 0–6–12 month schedule
with live attenuated vaccine had signiﬁcantly higher GMC  than
those vaccinated with a 0–6 month schedule of this vaccine and
those vaccinated with inactivated hepatitis A vaccine 7 years post-
vaccination.
4. Discussion
This systematic review found evidence for 15 years of sero-
protection against HAV-infection conferred by live attenuated
hepatitis A vaccines and 14 years of seroprotection against
HAV-infection achieved by inactivated hepatitis A vaccines [24].
Different vaccine schedules were assessed [9,24] but do not appear
to make signiﬁcant differences in outcomes. The percentage of par-
ticipants who maintained protective levels of antibodies varied by
schedule and indicated that a longer interval between the sec-
ond and last dose of inactivated hepatitis A vaccine administration
achieves a higher percentage (100%) at 14 years post-vaccination
using a three dose regimen [24]. While different dosages of the
inactivated vaccine did not produce signiﬁcantly different GMC,
[11] an increasing number of doses of live attenuated vaccine
revealed signiﬁcantly higher GMC  and a higher percentage of sero-
protection was  observed 8 years post vaccination [30,31]. This
ﬁnding may  have implications for the protective efﬁcacy and future
use of live attenuated vaccines, however, GMC  obtained from a
one dose administration of the live attenuated vaccine were still
sufﬁciently high to protect against HAV infection after 8 years.
The  duration of protection found from this review is partly in
line with the previous consensus group statement [14]. Increasing
evidence supporting immune memory and anamnestic response
in relation to HAV makes it likely that protection lasts longer than
the observed 15 years. Additionally, results from mathematical
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Table 1
Studies assessing long-term protection (≥60 months/5 years) of live attenuated hepatitis A vaccines.
Author Design Country Population Intervention Compari-son Outcomea Comment
Liu et al. [32] Observational
follow-up study; based
on  randomized vaccine
trial.
China  211 children;
randomly assigned to
dose and vaccine.
Live  attenuated
hepatitis A vaccine.
Group  A: 0–6–12
month  schedule.
Group B: 0–6 month
schedule.
Inactivated hepatitis A
vaccine;
Group  C: 0–6 month
schedule.
Between  different
follow-up times.
Between  inactivated
and  live attenuated
hepatitis A vaccine.
Between  different
schedules.
7  years after vaccination:
Group  A:
100%  seropositivity
GMC  336.8 mIU/ml
(95% CI 223.5–507.5)
Group  B:
100%  seropositivity
GMC  84.6 mIU/ml
(95% CI 66.4–107.8)
Group  C:
100%  seropositivity
GMC: 174.1 mIU/ml
(95% CI 123.3–245.7)
Signiﬁcant  difference
in GMC, in descending
order for the A, C,
B group.
Highest GMC  was
2938.1  mIU/ml, found
in group C, and it was
1315.6  mIU/ml and
1586 mIU/ml in group
A and B respectively.
Liu  et al. [30]Chinese Observational
follow-up study; based
on  randomized vaccine
trial.
China  Group A (three doses,
0–2–6  month
schedule): 42 children
Group  B (single dose):
110  age range 1–7
years.
Live  attenuated
hepatitis A vaccine (H2
strain).
Between  different
follow-up times.
Between  different
number of doses.
8  years after vaccination:
Group  A:
100%  seropositivity;
GMC: 918.2–480.6 mIU/ml
Group B:
71–75% seropositivity;
GMC:  80–89 mIU/ml
Signiﬁcant difference
between single and
booster dose recipients.
Wang et al. [31] Observational
follow-up study; based
on  clinical trial.
China  Group A (single dose):
85  children; age range
11–12.
Group  B (booster dose):
53  children; 48
followed  up
throughout.
Live  attenuated
hepatitis A vaccine.
Between different
follow-up times.
Between  different
numbers of doses.
8 years after vaccination:
Group  A:
71.6% seropositivity;
GMC: 89.0 mIU/ml (95% CI:
69.7–113.6)
Group B (booster dose):
98%  seropositivity;
GMC: 262.8 mIU/ml
(95% CI: 188.0–367.5)
Statistical  signiﬁcant
difference between
single and booster
dose recipients in
terms of anti-HAV
antibody titers.
Loss to follow up not
fully  explained.
Zhuang et al. [28] Observational
follow-up study; based
on  two trial sites.
China 220 children (124 boys,
96  girls), age range 1–3
years.
155  followed-up
throughout.
Live  attenuated
Hepatitis A vaccine;
single  dose.
Between  different
follow-up times.
10 years after vaccination:
No  hepatitis A case. 80.2%
seropositivity;
GMT:  145 mIU/ml.
CI not indicated.
Additional evaluation
of  vaccine impact on
hepatitis  A incidence.
Zhuang et al. [29] Observational
follow-up study.
China 220 children (124 boys,
96  girls), age range 1–3
years.
Live  attenuated
hepatitis A vaccine;
single  dose.
Between  different
follow-up times.
15 years after vaccination:
No  hepatitis A case. 81.3%
seropositivity;
GMT:  128 mIU/ml
GMC, geometric mean concentrations in mIU/ml.
a Seropositivity refers to protective anti-HAV seropositivity rate and the percentage of sero-conversion.
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Table 2
Studies assessing long-term protection (≥ 60 months/5 years) of inactivated hepatitis A vaccines.
Author Design Country Population  Intervention Comparison Outcomea Comment
Bian et al. [27] Observational follow-up
study.
China  Group A (inactivated
hepatitis A vaccine): 215
children;  average age 2.1
years.
110  followed throughout.
Group  B (live attenuated
hepatitis  A vaccine): 206
children;  average age 2.3
years.
85  followed throughout.
Inactivated hepatitis A
vaccine  (HAVRIX); 0–6
month  schedule.
Live attenuated hepatitis A
vaccine; single dose.
10 years after last dose of
inactivated hepatitis A
vaccine (group A):
No  hepatitis A case. 99.09%
seropositivity
GMC:  61.59 mIU/ml (95%
CI: 51.92–73.07)
3.6  years after live
attenuated  hepatitis A
vaccine  (group B):
97.65%  seropositivity
GMC:  67.87 mIU/ml (95%
CI: 36.38–86.30)
GMCs  were not
signiﬁcant different
between vaccine groups.
Study also reports on
memory  response after
booster  dose.
Bovier  et al. [25] Randomized clinical trial
(individuals  randomized to
intervention group) and
followed-up.
Switzerland 118  adults; age range
18–48.
54  adults followed
throughout.
Virosomal  hepatitis A
vaccine (EPAXAL);
0–12  month schedule.
Inactivated hepatitis A
vaccine  (HAVRIX).
Vaccines interchanged
5–6 years after booster
dose:
EPAXAL/EPAXAL group:
GMT:  1321 mIU/ml (95%
CI: 704–2482)
HAVRIX/HAVRIX group:
GMT:  1208 mIU/ml (95%
CI: 674–2164)
HAVRIX/EPAXAL group:
GMT:  859 mIU/ml
(95% CI: 457–1612)
EPAXAL/HAVRIX group:
GMT:  1191 mIU/ml (95%
CI: 690–2055)
Bovier et al. [13] Observational follow-up
study  (prospective)
Switzerland  332 adults vaccinated
1992–1995; age range
16–48.
130  agreed to participate in
follow-up and 127
followed  throughout.
Virosomal hepatitis A
vaccine (EPAXAL);
0–12  month schedule.
Between different
follow-up times (year 2, 3,
4, 5, 6, 7, 10–12).
9–11 years after second
dose/10–12  years after
initial  dose:
GMC:  526 mIU/ml
(95% CI: 439–630).
Subgroup analysis:
GMC  females:
741  mIU/ml
(95%  CI: 590–930)
GMC  males:
332  mIU/ml
(95%  CI: 266–414).
Year range derives from
different  time points of
initial  vaccination.
Study  provides additional
modeling  data.
Byrd  et al. [24] Observational follow-up
study  (prospective)
USA  144 children (3–6 years).
56  followed throughout.
Inactivated hepatitis A
vaccine  (HAVRIX).
A:  0–1–2 month schedule
B:  0–1–6 months
C:  0–1–12 months
schedule.
Between  different
follow-up times.
Between  different
schedules.
14  years after last dose:
Group  A:
86%  seropositivity GMC:
131  mIU/ml
(95%  CI: 65–265)
Group  B:
100%  seropositivity GMC:
227  mIU/ml
(95%  CI: 144–357)
Group  C:
100%  seropositivity
GMC  212 mIU/ml
(95% CI: 89–505)
Withdrawals not sign.
different  from those
followed  up throughout
No  stat. sign. differences in
anti-HAV levels by
vaccination  schedule and
sex.
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Table 2 (Continued)
Author Design Country Population Intervention Comparison Outcomea Comment
Crum-Cianﬂone et al. [26] Observational follow-up
study
(prospective)
USA  130 HIV-1 infected adults
(median  age 31 years,
mainly  males); vaccinated
1996–2003.
74  adults followed-up
throughout.
Inactivated hepatitis A
vaccine  (VAQTA or
HAVRIX);  administered
6–18  months apart after
HIV  diagnosis.
Between different
follow-up times.
With  historical data from
HIV-uninfected  adults
having  received 2 doses of
VAQTA, 0–6 month
schedule.
6–10 years (median time
8.2 years) after second HAV
vaccine  dose:
74  individuals/85% (95% CI:
75–92%) seropositivity
GMC:  64 mIU/ml
(95% CI: 2–2066)
Subgroup analysis:
GMC  among 54 individuals
with  higher CD4 counts
(≥350  cells/mm3): 70
(95%  CI: 2–2422)
GMC  among 20 individuals
with  CD4 counts below
350  cells/mm3:
50
(95%  CI: 1–1755)
GMC  among historically
HIV-uninfected individuals
(descriptive  comparison):
684  mIU/ml
(95%  CI: 564–831).
No vaccine-speciﬁc
analysis (HAVRIX and
VAQTA  in one)
Study  assesses other
factors  associated with
antibody response after
HAV  vaccination in
HIV-infected  persons
Lopez  et al. [23] Observational follow-up
study;  based on
randomized vaccine study.
Argentina  111 children vaccinated;
mean  age 156.06 months.
48  children followed
throughout.
Inactivated hepatitis A
vaccine  (AVAXIM);
0–6  month schedule.
Between different
follow-up times.
10 years after second dose:
97.9%  seropositivity
GMC: 390.91 mIU/ml (95%
CI: 282.2–499.5, range:
36–1860  mIU/ml)
Van Herck, Van Damme Observational follow-up
study;  based on
randomized vaccine trial.
Belgium  120 (study A)/194 (study B)
adults; age range 18–40.
58  (study A)/134 (study B)
adults followed
throughout.
Inactivated hepatitis A
vaccine  (HAVRIX);
A:  0–6 month schedule
B:  0–12 month schedule.
Between different
follow-up times.
Between  different
schedules.
5.5 years after second dose:
Study  A:
100% seropositivity
GMT: 522 mIU/ml
(95% CI: 398–685)
Study  B:
99.3% seropositivity
GMT:  749 mIU/ml
(95% CI: 604–929)
Not assessed if drop-outs
were  different in the two
groups  (misclassiﬁcation).
Study  provides additional
modeling  data.
Wiedermann  et al. [11] Observational follow-up
study;  based on
randomized vaccine trial.
Austria  110 adults vaccinated;
average  age 26.7; range
17–55  years.
59  adults followed
throughout.
Inactivated hepatitis A
vaccine  (candidate);
0–1–2–12  month schedule.
Between different
follow-up times (month 1,
4, 6, 18, 24, 36, and 84)
after  ﬁrst dose.
Between different dosage
groups  (180, 360, 720 El.U).
6 years after last dose/76
month  after last dose:
Dosage  180 El.U (28
individuals):
GMT: 506 mIU/ml (95% CI:
319–803)
Dosage 360 El.U (27
individuals):
GMT: 983 mIU/ml (95% CI:
662–1461)
Dosage 720 El. U (4
individuals):
GMT: 1587 mIU/ml (95%
CI: 622–4045)
Drop outs not described.
GMC, geometric mean concentrations in mIU/ml.
a Seropositivity refers to protective anti-HAV seropositivity rate and the percentage of sero-conversion.
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odels indicate that protective levels of antibody induced by
wo doses of inactivated hepatitis A vaccine can last for at
east 25 years [9]. Nevertheless, from the observed data, it
s not possible to make a statement on life-long protection
f HAV vaccines and there might be important considerations
egarding schedule and age, particularly for live attenuated
accines.
This review did not include studies conducted in populations
t high risk for HAV infection (e.g. people who live in places with
oor sanitation) given that they were all excluded on the basis
f short observation times and mainly targeting immunogenicity
nd safety of the vaccine. We  have included one study conducted
mong HIV-infected adults because of the long follow-up time and
he comparison with HIV-non infected individuals that was  done
n this study [26]. Although sufﬁciently protective levels persisted
ntil year 6–10 post hepatitis A vaccination, it is not possible to gen-
ralize this result to individuals with co-morbidities. Despite the
pcoming research on long-term immunologic response to hepati-
is A vaccine in HIV-positive individuals [26,33], too few data are
vailable.
The design of the included studies varied with respect to their
ntervention and comparison groups and makes it difﬁcult to gen-
ralize the overall ﬁnding to all HAV vaccines and schedules.
he interchangeability of inactivated and live attenuated hep-
titis A vaccines has been addressed in two studies of which
ne used different observation periods (3.6 years for live attenu-
ted versus 10 years for inactivated vaccines [27]), which makes
he comparison less relevant. Liu et al. [32] found signiﬁcant
ifferences in GMC  between the two vaccine types 7 years post-
accination and between different schedules of administration of
ttenuated vaccine. The overall result was that live attenuated
accine using a 0–6–12 months schedule achieved signiﬁcantly
igher GMC  as compared to another schedule with the same vac-
ine and compared to inactivated hepatitis A vaccine. Although
oth vaccine types revealed sufﬁciently high GMC  to be protec-
ive after 7 years, there may  be differences regarding lifelong
rotective effects. Since this is the only study comparing the
wo vaccine types regarding their long-term efﬁcacy and since
his was done in children only in China, the results cannot be
eneralized.
.1. Limitations of the studies
The  quality of the available studies was often affected by study
esign and reporting of loss to follow-up and only one study ran-
omized individuals to the intervention group [25]. Although some
tudies randomized participants to different dosage or schedule at
he time of primary vaccination, all studies were nonrandomized
nd observational in their design of long-term antibody persis-
ence. This resulted in high loss-to-follow up with increasing
ollow-up times and a relatively low number of individuals agreeing
n participation after having received the required vaccine. Over-
ll, the drop out rate exceeded 50% at maximum follow-up in the
ajority of cases. Given the nature of study design, it was  also not
ossible to rule out whether natural exposure to HAV can act or
cted as a natural booster among the study participants followed
p for many years. This question is however, crucial to be addressed
n future research. Not all studies reported conﬁdence intervals
round the observed GMT/GMC and few indicated the range of
MT/GMC.
.2. Limitations of this reviewGeneral  bias potentially affecting systematic reviews using elec-
ronic databases can occur from late indexing of research and
nder-representation of literature from developing countries in1 (2012) 3– 11
electronic  databases [34]. Most of the studies found on long-term
protective effects of hepatitis A vaccine were conducted in high-
income countries and in China. There were not much data published
and available from other world regions, particularly from low
income countries.
We  restricted this review to studies on monovalent hepatitis A
vaccines, which have been licensed for individuals aged ≥1 year.
Studies on combination vaccine containing hepatitis A and B vac-
cines were excluded since these vaccines have only been licensed
for use in children aged 1 year and older in a few countries and
the majority of them are licensed for adults (aged ≥18 years).
Nevertheless, combination vaccines are increasingly used and long-
term protective effects should be evaluated speciﬁcally for these
products.
4.3. Future research needs and conclusions
The data found from our systematic review supports the need
further investigations evaluating antibody levels beyond 15 years
post-vaccination with inactivated and live attenuated hepatitis A
vaccines, as well as the interplay between detectable antibody lev-
els and memory responses to HAV. This is particularly relevant for
individuals with other chronic infections such as HIV and for under-
standing the pathogenesis of HAV-related fulminant liver failure.
Several  factors can impact the long-term protection of vaccines
in general and hepatitis A vaccine in particular. Differences between
males and females have been shown in regard to both absolute
GMCs and their change with time. Females were more likely to have
higher GMCs than males but declines in GMCs were more moder-
ate in males later after vaccine administration, resulting in a slightly
lower estimated duration of protection in females [13]. Reporting
of sex- and age-speciﬁc anti-HAV antibody persistence was  less
common across the studies but differences should be assessed rou-
tinely and be accompanied by statistical analysis. Since all studies
on long-term protection of live attenuated hepatitis A vaccine were
done in children, it is important to obtain data from adult cohorts
as well.
There is a need for a clear understanding of “protective lev-
els” when discussing surrogates of protection. The lower limit
of anti-HAV antibody titer requirement to prevent HAV infection
is not standardized and some studies on inactivated HAV vac-
cine use a anti-HAV antibody titer of 10 mIU/ml as lower cut-off
[11–13,25,26] instead of the 20 mIU/ml. Currently, available studies
on this subject are of experimental nature [35] or done in vitro [36]
and more clinical and applied research is encouraged on this issue.
Furthermore, assays for anti-HAV are not standardized, which may
impact on comparability.
The  cost-utility and the impact of herd immunity are two other
subjects that need to be investigated further in the context of
long-term protection from hepatitis A vaccines. Cost-effectiveness
of hepatitis A vaccines depends on several factors including on
country-speciﬁc endemicity levels, herd immunity, vaccine cover-
age and within country variations and studies focusing on amounts
of costs saved need to be seen in context of estimated health con-
sequences [37,38].
With  respect to inactivated hepatitis A vaccines, which are rec-
ommended to be administered using a two-dose schedule, research
should be stimulated to a closer look at the number of doses really
needed to achieve long-term protection against hepatitis A infec-
tion since protection may  be largely conferred by the ﬁrst dose of
the vaccine. Single or ﬂexible dose administration of inactivated
hepatitis A vaccines might be an option for some countries and
a review of existing data on this topic is important as well as an
incentive to directly compare single and full dose administration
in relation to long-term protection.
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